vTv Therapeutics to Participate in the H.C. Wainwright “HCW@Home” Series
vTv Therapeutics (VTVT) announced its participation in the virtual H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Details
News Market Reaction – VTVT
The recorded move for VTVT in the trading session of this news was -0.30%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
HIGH POINT, N.C., June 11, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that management will participate in the H.C. Wainwright “HCW@Home” Series, being held virtually on Thursday, June 12, 2025.
Conference details are as follows:
H.C. Wainwright “HCW@Home with vTv Therapeutics”
Format: Fireside Chat
Moderator: Emily Bodnar, Director, H.C. Wainwright
vTv Therapeutics Speakers:
- Paul Sekhri, Chairman of the Board, President & Chief Executive Officer
- Thomas Strack, MD, Chief Medical Officer
- Carmen Valcarce, Ph.D., Executive Vice President, Chief Scientific Officer
- Michael Tung, MD, MBA, Chief Financial Officer
Date: Thursday, June 12, 2025
Time: 10:00 AM ET
Webcast Link: Register here
The webcast of the event will be accessible from News & Events page of the vTv website.
About vTv Therapeutics
vTv Therapeutics Inc. is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. vTv's clinical pipeline is led by cadisegliatin, currently in a Phase 3 trial, a potential first-in-class oral glucokinase activator being investigated for the treatment of type 1 diabetes. vTv and its development partners are investigating multiple molecules into different indications for chronic diseases. Learn more at vtvtherapeutics.com or follow the company on LinkedIn or X.
Investor Contact
John Fraunces
LifeSci Advisors, LLC
917-355-2395
jfraunces@lifesciadvisors.com
Media Contact
Caren Begun
TellMed Strategies
201-396-8551
caren.begun@tmstrat.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.